[go: up one dir, main page]

HUP9903405A1 - Metalloproteináz-inhibitor hatású ciklusos és heterociklusos N-szubsztituált-alfa- imino-hidroxámsavak, és -karbonsavak, előállításuk és alkalmazásuk - Google Patents

Metalloproteináz-inhibitor hatású ciklusos és heterociklusos N-szubsztituált-alfa- imino-hidroxámsavak, és -karbonsavak, előállításuk és alkalmazásuk

Info

Publication number
HUP9903405A1
HUP9903405A1 HU9903405A HUP9903405A HUP9903405A1 HU P9903405 A1 HUP9903405 A1 HU P9903405A1 HU 9903405 A HU9903405 A HU 9903405A HU P9903405 A HUP9903405 A HU P9903405A HU P9903405 A1 HUP9903405 A1 HU P9903405A1
Authority
HU
Hungary
Prior art keywords
powder
iminohydroxamic
heterocyclic
cyclic
preparation
Prior art date
Application number
HU9903405A
Other languages
English (en)
Inventor
Eckart Bartnik
Burkhard Haase
Manfred Schudok
Wilfried Schwab
Werner Thorwart
Klaus-Ulrich Weithmann
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26020318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9903405(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1995142189 external-priority patent/DE19542189A1/de
Priority claimed from DE1996112298 external-priority patent/DE19612298A1/de
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of HUP9903405A1 publication Critical patent/HUP9903405A1/hu
Publication of HUP9903405A3 publication Critical patent/HUP9903405A3/hu
Publication of HU223086B1 publication Critical patent/HU223086B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

A találmány szerinti vegyületek (I) általánős képletében R4 jelentése adőtt esetben szűbsztitűált naftilcsőpőrt, -B-C6H4-X-R2,-B-C6H4-Z vagy -B-Z1 általánős képletű csőpőrt, ahől B jelentésekővalens kötés vagy alkilén- vagy viniléncsőpőrt, C6H4feniléncsőpőrtőt jelent, X jelentése kővalens kötés, őxigénatőm,karbőnil-, hidrőxi-metilén-csőpőrt vagy -S(O)p-képletű csőpőrt, ahől pértéke 0, 1 vagy 2, R2 jelentése adőtt esetben szűbsztitűáltfenilcsőpőrt, Z és Z1 - jelentése egymástól függetlenül, - adőttesetben szűbsztitűált heterőciklűsős csőpőrt, A jelentése hidrőxi-aminő-karbőnil- vagy karbőxilcsőpőrt, Q jelentése adőtt esetben szűbsztitűált fenilén-, tienilén-,pirrőlilén- vagy imidazőliléncsőpőrt, m és n értéke 0, 1 vagy 2, bizőnyős feltételekkel. (I) ŕ
HU9903405A 1995-11-13 1996-11-04 Metalloproteináz-inhibitor hatású ciklusos és heterociklusos N-szubsztituált-alfa-imino-hidroxámsavak és karbonsavak, előállításuk és alkalmazásuk HU223086B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1995142189 DE19542189A1 (de) 1995-11-13 1995-11-13 Cyclische N-substituierte alpha-Iminohydroxamsäuren
DE1996112298 DE19612298A1 (de) 1996-03-28 1996-03-28 Heterocyclische N-substituierte alpha-Iminohydroxamsäuren
PCT/EP1996/004776 WO1997018194A1 (de) 1995-11-13 1996-11-04 CYCLISCHE UND HETEROCYCLISCHE N-SUBSTITUIERTE α-IMINOHYDROXAM- UND CARBONSÄUREN

Publications (3)

Publication Number Publication Date
HUP9903405A1 true HUP9903405A1 (hu) 2000-04-28
HUP9903405A3 HUP9903405A3 (en) 2000-12-28
HU223086B1 HU223086B1 (hu) 2004-03-29

Family

ID=26020318

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903405A HU223086B1 (hu) 1995-11-13 1996-11-04 Metalloproteináz-inhibitor hatású ciklusos és heterociklusos N-szubsztituált-alfa-imino-hidroxámsavak és karbonsavak, előállításuk és alkalmazásuk

Country Status (20)

Country Link
US (3) US6207672B1 (hu)
EP (1) EP0861236B2 (hu)
JP (1) JP4638560B2 (hu)
KR (1) KR100475206B1 (hu)
CN (1) CN1131215C (hu)
AT (1) ATE213232T1 (hu)
AU (1) AU707707B2 (hu)
BR (1) BR9611479B1 (hu)
CA (1) CA2237590C (hu)
CZ (1) CZ297550B6 (hu)
DE (1) DE59608740D1 (hu)
DK (1) DK0861236T4 (hu)
ES (1) ES2170884T5 (hu)
HU (1) HU223086B1 (hu)
MX (1) MX9803753A (hu)
PL (1) PL186869B1 (hu)
PT (1) PT861236E (hu)
RU (1) RU2164914C2 (hu)
TR (1) TR199800849T2 (hu)
WO (1) WO1997018194A1 (hu)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990072009A (ko) * 1995-08-12 1999-09-27 게리 이. 프리드만 메탈로프로티나제 방해제, 그를 포함하는 약제 조성물 및 약제로서의 용도, 그리고 그의 제조방법 및 제조에 유용한 중간체
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TR199900382T2 (xx) * 1996-08-28 1999-05-21 The Procter & Gamble Company Heterosiklik metaloproteaz inhibit�rleri.
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
AU4812697A (en) * 1996-10-22 1998-05-15 Pharmacia & Upjohn Company Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
SG88737A1 (en) * 1996-10-30 2002-05-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
WO1998032748A1 (en) * 1997-01-23 1998-07-30 F. Hoffmann-La Roche Ag Sulfamide-metalloprotease inhibitors
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
JP2003524572A (ja) * 1997-08-04 2003-08-19 アムジエン・インコーポレーテツド ヒドロキサム酸置換縮合複素環メタロプロテイナーゼ阻害剤
BR9812727A (pt) * 1997-10-06 2000-08-22 American Cyanamid Co Preparação e uso de ácidos orto-sulfonamido bicìclico hetero aril hidroxâmicos como metalo proteinase matriz e inibidores de tace
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
FR2771095B1 (fr) * 1997-11-14 1999-12-17 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6335329B1 (en) 1997-12-19 2002-01-01 Amgen Inc. Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
HUP0100277A3 (en) * 1998-01-27 2002-03-28 American Cyanamid Company Madi 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as metalloproteinase inhibitors, process for their preparation and pharmaceutical compositions containing them
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
AU3982599A (en) * 1998-05-14 1999-11-29 Du Pont Pharmaceuticals Company Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
AU6228499A (en) * 1998-10-22 2000-05-08 Akzo Nobel N.V. Tetrahydropyridopyridine derivatives and intermediates for producing the same
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
GB9903598D0 (en) * 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
GB0011409D0 (en) * 2000-05-11 2000-06-28 Smithkline Beecham Plc Novel compounds
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
FR2821842B1 (fr) * 2001-03-07 2003-05-09 Servier Lab Nouveaux derives d'inhibiteurs de mettalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002324716A1 (en) 2001-08-17 2003-03-03 Bristol-Myers Squibb Company Patent Department Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
MXPA04004010A (es) 2001-11-01 2004-07-23 Wyeth Corp Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
RU2223703C2 (ru) * 2002-02-13 2004-02-20 Иркутский государственный институт усовершенствования врачей Способ лечения передней хронической нестабильности коленного сустава
DE10209299A1 (de) * 2002-03-02 2003-09-18 Aventis Pharma Gmbh Cyclische N-substituierte alpha-Iminocarbonsäuren zur selektiven Inhibierung von Kollagenase
US6716853B2 (en) 2002-03-02 2004-04-06 Aventis Pharma Deutschland Gmbh Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase
AU2003304456A1 (en) 2002-12-23 2005-03-16 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
WO2004060892A1 (ja) * 2002-12-27 2004-07-22 Japan Tobacco Inc. 縮合ｎ含有ヘテロ環化合物及びその医薬用途
DE10300015A1 (de) * 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen
DE10344936A1 (de) 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
US7205315B2 (en) 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
DE10351904A1 (de) * 2003-11-06 2005-06-09 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von cyclischen N-substituierten alpha-Iminocarbonsäure
US7244845B2 (en) * 2003-11-06 2007-07-17 Sanofi-Aventis Deutschland Gmbh Process for preparing cyclic N-substituted alpha-imino carboxylic acids
DE102004004974A1 (de) * 2004-01-31 2005-08-18 Aventis Pharma Deutschland Gmbh Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
US7705017B2 (en) * 2004-05-03 2010-04-27 En Vivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
DE102004031850A1 (de) * 2004-06-30 2006-01-26 Sanofi-Aventis Deutschland Gmbh Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US7601838B2 (en) * 2004-12-28 2009-10-13 Council Of Scientific And Industrial Research 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents
DE102005002500A1 (de) * 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
BRPI0610128B1 (pt) 2005-05-13 2021-12-07 Topotarget Uk Limited Composição farmacêutica, e, uso de uma composição
WO2007045661A1 (en) * 2005-10-20 2007-04-26 Nordic Bioscience Diagnostics A/S Detection or quantification of aggrecan and its fragments
GB0526257D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
CA2695504C (en) 2007-08-03 2017-05-30 Nucitec S.A. De C.V. Compositions and methods for treatment and prevention of osteoarthritis
JP5501230B2 (ja) 2007-08-07 2014-05-21 アボット ゲーエムベーハー ウント カンパニー カーゲー セロトニン５−ｈｔ６受容体の調節に応答する障害の治療に好適なキノリン化合物
BRPI0821247A2 (pt) 2007-12-14 2015-06-16 Univ Georgetown Inibidores de histona deacetilase
ES2527589T3 (es) * 2008-04-24 2015-01-27 Msd K.K. Inhibidor de la enzima de elongación de ácidos grasos de cadena larga que comprende un derivado de arilsulfonilo como principio activo
KR20110040911A (ko) * 2008-07-14 2011-04-20 노파르티스 아게 선택적 히드록삼산계 ｍｍｐ-12 및 ｍｍｐ-13 억제제
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947270B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
EP3199534B1 (en) 2016-02-01 2018-09-05 Galderma Research & Development Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
EP3717481B1 (en) 2017-11-27 2023-03-01 Council of Scientific & Industrial Research Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
CN119565781B (zh) * 2024-12-20 2026-01-02 中南大学 一种金属离子-含氮芳杂环配合物捕收剂及其制备方法和在钨矿浮选中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2125778A1 (en) † 1970-06-02 1971-12-16 Hokuriku Seiyaku Co Ltd , Katsuyama, Fukui (Japan) Isoquinobenzodiazepine derivs - cns depressants hypotensives etc - prepd from isoquinoline-carboxylic acids
TW201303B (hu) * 1990-07-05 1993-03-01 Hoffmann La Roche
JPH04210675A (ja) † 1990-12-13 1992-07-31 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
US5219851A (en) † 1991-03-05 1993-06-15 Warner-Lambert Company Tetrahydroisoquinoline-type renin inhibiting peptides
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
CA2193691A1 (en) † 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors
DE10003007C2 (de) * 2000-01-25 2002-06-13 Schunk Metall & Kunststoff Erdungskontakt

Also Published As

Publication number Publication date
TR199800849T2 (xx) 1998-07-21
US6207672B1 (en) 2001-03-27
HU223086B1 (hu) 2004-03-29
BR9611479B1 (pt) 2009-01-13
EP0861236B1 (de) 2002-02-13
PL186869B1 (pl) 2004-03-31
ES2170884T5 (es) 2007-04-01
RU2164914C2 (ru) 2001-04-10
ES2170884T3 (es) 2002-08-16
US6815440B2 (en) 2004-11-09
US20010011134A1 (en) 2001-08-02
CN1202156A (zh) 1998-12-16
BR9611479A (pt) 1999-07-13
AU707707B2 (en) 1999-07-15
PT861236E (pt) 2002-07-31
CZ145398A3 (cs) 1998-08-12
CA2237590A1 (en) 1997-05-22
WO1997018194A1 (de) 1997-05-22
CN1131215C (zh) 2003-12-17
EP0861236A1 (de) 1998-09-02
JP2000500145A (ja) 2000-01-11
US20030176432A1 (en) 2003-09-18
KR100475206B1 (ko) 2005-12-16
DK0861236T3 (da) 2002-05-21
MX9803753A (es) 1998-10-31
DE59608740D1 (de) 2002-03-21
EP0861236B2 (de) 2006-08-16
CZ297550B6 (cs) 2007-02-07
DK0861236T4 (da) 2006-12-18
JP4638560B2 (ja) 2011-02-23
ATE213232T1 (de) 2002-02-15
HUP9903405A3 (en) 2000-12-28
KR19990067685A (ko) 1999-08-25
US6573277B2 (en) 2003-06-03
CA2237590C (en) 2011-07-19
AU7562496A (en) 1997-06-05
PL326702A1 (en) 1998-10-26

Similar Documents

Publication Publication Date Title
HUP9903405A1 (hu) Metalloproteináz-inhibitor hatású ciklusos és heterociklusos N-szubsztituált-alfa- imino-hidroxámsavak, és -karbonsavak, előállításuk és alkalmazásuk
NL971014I1 (nl) Heterocyclische verbindingen.
NO861481L (no) Analogifremgangsmaate for fremstilling av farmasoeytisk aktive heterocykliske amid-derivater.
NO894943L (no) Enzym-hemmende urinstoffderivater av dipeptider.
ES2053609T3 (es) Derivados de urea inhibidores de lipoxigenasa.
DE69132006D1 (de) Thiazolederivate als inhibitoren von aktivem sauerstoff
DE3781620D1 (de) 1,4,7,10-tetraazacyclododecan-derivate.
ATE194335T1 (de) 4,5-diaryloxazol-derivate
DE69901006D1 (de) Benzothiophen-, Benzofuran- und Indolderivate, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
DK426289A (da) Spiroforbindelser og farmaceutisk praeparat indeholdende en saadan forbindelse
DE69208478D1 (de) Amid derivate von vitamin d
DK0487620T3 (da) Hidtil ukendte aminosyrederivater, fremgangsmåde til fremstilling heraf og terapeutisk anvendelse heraf
ES2046229T3 (es) Composicion antiulcerosa.
ATE155127T1 (de) Benzamid-derivate
ATE83481T1 (de) Fuenfgliedrige heterocyclische derivate von n'substituiertenn,n'-diacylhydrazinen.
ATE219065T1 (de) Arylpiperidin- und arylpiperazin-derivate und sie enthaltende arzneimittel
BE890399A (fr) Bisulfures intra- ou intermoleculaires de derives de cysteine
FI962236L (fi) Heterosykliset bentseenisulfonyyli-imiinijohdannaiset IL-1:n toiminnan inhibiittoreina
FR2347349A1 (fr) Derives d'acides phenoxymaloniques et composition herbicide les contenant
NO892718D0 (no) Anvendelse av en karbonylforbindelse.
DE68909025D1 (de) Mittel zur Verhinderung von Zahnbelagbildung.
FR2303004A1 (fr) Derives d'acides dicarboxyliques contenant des heterocycles
EP0327877A3 (de) Peptid-Renininhibitoren
ATE65986T1 (de) Propanolabkoemmlinge.
ATE121394T1 (de) Konjugierte gamma-hydroxybutenolid-derivate und sie als aktiver wirkstoff enthaltende mittel gegen magengeschwüre.

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20040119

MM4A Lapse of definitive patent protection due to non-payment of fees